Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Spinal cord injury (SCI) causes paralysis and muscle atrophy and leads to weight gain and obesity. Obesity directly contributes to functional impairment and cardiometabolic dysfunction. There is a critical need to reduce the growing prevalence of obesity and cardiometabolic disease after SCI. My overall objective in this project is to gather crucial feasibility data on time restricted eating (TRE), a novel form of intermittent fasting. TRE is a straightforward method to induce weight loss without the need for calorie counting. TRE allows individuals to eat all their daily calories in a time restricted window and fast outside that window. A growing body of literature supports the safety and efficacy of TRE. Given the feasibility, high adherence, and substantial benefits of TRE in able-bodied individuals, it is important to test TRE to determine its feasibility in Veterans with SCI. The investigators will first test this intervention in Veterans with paraplegia, who are at greatest risk of muscle-joint upper body injury given the need to support body weight during activity. The investigators will determine adherence to a TRE window for 6-weeks duration in a convenience sample of Veterans with paraplegia and obesity. Based on the expected outcomes of good adherence, this study will lay the groundwork for future work by informing the design of a randomized controlled trial to test the efficacy of TRE to facilitate weight loss and improve function.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Females who are pregnant (tested via urinary hCG), planning to become pregnant in the next 6 months, or breast-feeding
A member of the SCI/D registry through the Syracuse VA, with a qualifying diagnosis of MS or ALS
Diagnosis of heart failure
Diagnosis of diabetes mellitus, type 1
Diagnosis of diabetes mellitus, type 2, and on insulin or other antidiabetic agent with high incidence of hypoglycemia
o Of note, antidiabetic agents with low incidence of hypoglycemia are: metformin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP4 inhibitors, alpha glucosidase inhibitors, thiazolidinediones (as discussed with VA pharmacist)
Diagnosis of End Stage Renal Disease
Diagnosis of dementia
Diagnosis of orthostatic hypotension and prescribed midodrine or fludrocortisone
History of syncopal episode in the month prior to the study
History of significant weight loss (> 10% body weight) in the month prior to the study
History of eating disorders (e.g., anorexia or bulimia) within the last five years, or clearance from a mental health provider
History of active suicidal ideation in the last six months, or clearance from a mental health provider
Currently prescribed weight loss medication (e.g., liraglutide)
Currently prescribed corticosteroids
Current acute medical issues including cancer, sepsis, advanced liver failure, porphyria, or uncontrolled hyperthyroidism
Primary purpose
Allocation
Interventional model
Masking
15 participants in 1 patient group
Loading...
Central trial contact
Michael L Kubala; Geoffrey V Henderson, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal